What Lies Beneath: Diagnostic Challenges of Prurigo Nodularis
Provided by RMEI Medical Education, LLC
Target Audience
Dermatology and primary care clinicians
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Utilize strategies to improve prurigo nodularis (PN) symptom recognition and diagnosis
- Identify elements of type 2 inflammation that play a role in PN pathogenesis that may be amenable to treatment
Faculty
Shawn Kwatra, MD
Associate Professor, Dermatology and Oncology
Director, Johns Hopkins Itch Center
Johns Hopkins University School of Medicine
Baltimore, MD
Shawn Kwatra, MD, is an associate professor of dermatology at the Johns Hopkins University School of Medicine in Baltimore, MD and the director of the Johns Hopkins Itch Center. Dr Kwatra received his medical degree from Wake Forest University School of Medicine in North Carolina. He then completed his residency in dermatology at John Hopkins University School of Medicine. Dr Kwatra is board certified in dermatology.
Dr Kwatra’s areas of clinical expertise include, chronic pruritus, prurigo nodularis, atopic dermatitis, and dermatology for ethnic skin. Dr Kwatra is funded by the National Institutes of Health, the Skin of Color Society, the Dermatology Foundation, and the Society for Investigative Dermatology. He has authored or co-authored over 200 publications and is a member of the Board of Directors of the Skin of Color Society.
Sarah S. Chisolm, MD
Assistant Professor and Director, Clinical Trials, Department of Dermatology
Emory University
Managing Director, ITCH-E (Itch Translational and Clinical Home at Emory)
Staff Physician, VISN 7, VA
Emory University Hospital
Atlanta, GA
Sarah S. Chisolm, MD, is a dermatologist at Emory University Hospital in Atlanta, GA. Dr Chisolm completed both her undergraduate and medical degrees at the University of North Carolina at Chapel Hill. She completed a fellowship in autoimmune dermatology at Stanford University and a fellowship in complex medical dermatology at University of California San Francisco. Her residency was completed at Vidant Medical Center in Greenville, NC. Dr Chisolm is board certified in dermatology.
Dr Chisolm’s interests are in atopic dermatitis, pruritus, prurigo nodularis, and allergic contact dermatitis. Her current goal is to continue the growth of the itch center and clinical trials pipeline at Emory to better serve patients with itch, atopic dermatitis, prurigo nodularis, and other inflammatory skin disease.
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Sarah S. Chisolm, MD, has relevant financial relationships with AbbVie, AstraZeneca, CSL Vifor, Galderma, Janssen Pharmaceuticals, Kimberly-Clark, Kiniksa Pharmaceuticals, Pfizer, Regeneron, Sanofi, Trevi Therapeutics, VYNE Therapeutics, Inc., formerly Menlo Therapeutics (Advisor); Amgen, Incyte Corporation, Pfizer (Researcher).
Shawn Kwatra, MD, has relevant financial relationships with AbbVie, Aslan Pharmaceuticals, Arcutis Biotherapeutics, Inc., Castle Biosciences, Celldex Therapeutics, Inc., Galderma, Genzada Pharmaceuticals USA, Inc., Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi (Consultant); Galderma, Incyte Corporation, Pfizer, Sanofi (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Resources
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.